|
Volumn 26, Issue SPEC. 2, 2002, Pages
|
Treatment of chronic hepatitis C in special groups;Hépatite chronique C traitement des groupes particuliers
a b a,c |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA2B INTERFERON;
AMANTADINE;
ANTIDEPRESSANT AGENT;
ANTIRETROVIRUS AGENT;
ANTIVIRUS AGENT;
FLUOXETINE;
IMMUNOSUPPRESSIVE AGENT;
INTERFERON;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
NORTRIPTYLINE;
PEGINTERFERON ALPHA2A;
RIBAVIRIN;
SERTRALINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
BLOOD TRANSFUSION;
CHRONIC HEPATITIS;
CLINICAL TRIAL;
CONFERENCE PAPER;
DEPRESSION;
DRUG EFFICACY;
GENOTYPE;
HEMODIALYSIS;
HEMOPHILIA;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY DISEASE;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MENTAL DISEASE;
THALASSEMIA;
TREATMENT OUTCOME;
VIRUS HEPATITIS;
ACUTE DISEASE;
ADULT;
ANTIVIRAL AGENTS;
BONE MARROW TRANSPLANTATION;
CHILD;
DRUG THERAPY, COMBINATION;
FOLLOW-UP STUDIES;
HEMOPHILIA A;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON-ALPHA;
KIDNEY TRANSPLANTATION;
LIVER TRANSPLANTATION;
MENTAL DISORDERS;
RENAL DIALYSIS;
RIBAVIRIN;
THALASSEMIA;
TIME FACTORS;
|
EID: 0036262502
PISSN: 03998320
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (8)
|
References (134)
|